According to the arm Phase II study which comprised 126 patients receiving BIBF 1120 as first-line treatment in combination with mFOLFOX6 showed a median progression-free survival of 10.6 months.
This was found to be equivalent to bevacizumab plus mFOLFOX6.
Among the patients, only 34.1% of those who took BIBF 1120 experienced any kind of serious adverse events, versus 53.7% of those taking bevacizumab.
Patients receiving BIBF 1120 had a similar progression-free survival rate at 9 months to those taking bevacizumab (63% vs. 69%).
Phase III trials with larger patient populations will be considered to confirm these positive results and to further investigate the potential of BIBF 1120 in mCRC, the company says.